Payment overview · 2025
General Payments
$487.91
27 reported records · 16 companies
Healthcare provider profile · identity verified
Atul Bhasin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FREEHOLD, NJ · NPI 1619989639
Verified facts
What the public records show
CMS Open Payments records show Atul Bhasin, MD received $487.91 in general payments during 2025 across 27 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1843 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.10 | 17.2% | 5 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $60.76 | 12.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.53 | 12.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.18 | 9.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.45 | 6.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.17 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.78 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.84 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.75 | 3.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.57 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.77 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.75 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.64 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.21 | 3.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $13.93 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.48 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.91 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $102.85 | 6 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $60.76 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $60.53 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.18 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.17 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 212 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 54 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
107 | 104 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
212 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
124 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1843 | 267 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
54 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2708 | 506 |
| Eliquis | Apixaban | 1843 | 267 |
| Amlodipine Besylate | Amlodipine Besylate | 1798 | 344 |
| Furosemide | Furosemide | 1741 | 367 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1693 | 312 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1581 | 388 |
| Metoprolol Succinate | Metoprolol Succinate | 1125 | 260 |
| Potassium Chloride | Potassium Chloride | 1080 | 214 |
| Gabapentin | Gabapentin | 1051 | 195 |
| Mirtazapine | Mirtazapine | 1051 | 223 |
| Sertraline Hcl | Sertraline Hcl | 1039 | 179 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1015 | 180 |
| Tamsulosin Hcl | Tamsulosin Hcl | 869 | 177 |
| Escitalopram Oxalate | Escitalopram Oxalate | 861 | 162 |
| Donepezil Hcl | Donepezil Hcl | 858 | 150 |
| Losartan Potassium | Losartan Potassium | 841 | 163 |
| Clopidogrel | Clopidogrel Bisulfate | 730 | 150 |
| Divalproex Sodium | Divalproex Sodium | 688 | 123 |
| Memantine Hcl | Memantine Hcl | 677 | 100 |
| Metformin Hcl | Metformin Hcl | 663 | 118 |
| Lisinopril | Lisinopril | 636 | 122 |
| Omeprazole | Omeprazole | 633 | 105 |
| Carvedilol | Carvedilol | 593 | 115 |
| Quetiapine Fumarate | Quetiapine Fumarate | 551 | 106 |
| Trazodone Hcl | Trazodone Hcl | 536 | 114 |
| Xarelto | Rivaroxaban | 534 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 499 | 106 |
| Levetiracetam | Levetiracetam | 463 | 71 |
| Simvastatin | Simvastatin | 368 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 356 | 67 |
| Famotidine | Famotidine | 338 | 93 |
| Spironolactone | Spironolactone | 332 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 298 | 43 |
| Nystatin | Nystatin | 292 | 105 |
| Valsartan | Valsartan | 288 | 59 |
| Midodrine Hcl | Midodrine Hcl | 287 | 97 |
| Paroxetine Hcl | Paroxetine Hcl | 284 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 283 | 44 |
| Finasteride | Finasteride | 280 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 276 | 39 |
| Cefuroxime | Cefuroxime Axetil | 275 | 199 |
| Allopurinol | Allopurinol | 273 | 54 |
| Latanoprost | Latanoprost | 273 | 51 |
| Ezetimibe | Ezetimibe | 271 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 266 | 69 |
| Alprazolam | Alprazolam | 252 | 72 |
| Prednisone | Prednisone | 250 | 100 |
| Buspirone Hcl | Buspirone Hcl | 240 | 53 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 239 | 47 |
| Glimepiride | Glimepiride | 233 | 39 |
| Doxazosin Mesylate | Doxazosin Mesylate | 230 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 230 | 52 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 224 | 108 |
| Januvia | Sitagliptin Phosphate | 224 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 218 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 45 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 215 | 45 |
| Jardiance | Empagliflozin | 212 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 211 | 38 |
| Torsemide | Torsemide | 211 | 43 |
| Sucralfate | Sucralfate | 199 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 189 | 119 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 184 | 52 |
| Tradjenta | Linagliptin | 184 | 22 |
| Lorazepam | Lorazepam | 173 | 68 |
| Warfarin Sodium | Warfarin Sodium | 173 | 17 |
| Baclofen | Baclofen | 167 | 21 |
| Montelukast Sodium | Montelukast Sodium | 160 | 41 |
| Tramadol Hcl | Tramadol Hcl | 158 | 75 |
| Risperidone | Risperidone | 152 | 26 |
| Lactulose | Lactulose | 147 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 48 |
| Farxiga | Dapagliflozin Propanediol | 137 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 56 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 127 | 21 |
| Entresto | Sacubitril/Valsartan | 124 | 20 |
| Bumetanide | Bumetanide | 123 | 32 |
| Cephalexin | Cephalexin | 122 | 88 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 119 | 98 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 21 |
| Metformin Hcl Er | Metformin Hcl | 113 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 111 | 55 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 107 | 104 |
| Atenolol | Atenolol | 105 | 21 |
| Alendronate Sodium | Alendronate Sodium | 103 | 20 |
| Memantine Hcl Er | Memantine Hcl | 103 | 15 |
| Digoxin | Digoxin | 102 | 23 |
| Olanzapine | Olanzapine | 101 | 22 |
| Brilinta | Ticagrelor | 100 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 65 |
| Methenamine Hippurate | Methenamine Hippurate | 98 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 95 | 17 |
| Bupropion Xl | Bupropion Hcl | 94 | 24 |
| Azithromycin | Azithromycin | 93 | 63 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 17 |
| Enoxaparin Sodium | Enoxaparin Sodium | 91 | 16 |
| Nifedipine Er | Nifedipine | 90 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 64 |
| Lamotrigine | Lamotrigine | 86 | 14 |
| Novolog Flexpen | Insulin Aspart | 86 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 53 |
| Carbamazepine | Carbamazepine | 83 | suppressed |
| Myrbetriq | Mirabegron | 83 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 79 | 12 |
| Procrit | Epoetin Alfa | 78 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 77 | suppressed |
| Folic Acid | Folic Acid | 77 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 17 |
| Rivastigmine | Rivastigmine | 77 | 13 |
| Glipizide | Glipizide | 76 | 21 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 75 | 19 |
| Nystop | Nystatin | 74 | 41 |
| Breo Ellipta | Fluticasone/Vilanterol | 72 | 22 |
| Propranolol Hcl | Propranolol Hcl | 71 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 71 | 32 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 69 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 16 |
| Retacrit | Epoetin Alfa-Epbx | 67 | 13 |
| Levofloxacin | Levofloxacin | 65 | 44 |
| Clonazepam | Clonazepam | 64 | 22 |
| Vancomycin Hcl | Vancomycin Hcl | 64 | 17 |
| Aripiprazole | Aripiprazole | 62 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 62 | 22 |
| Pregabalin | Pregabalin | 62 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 61 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 20 |
| Insulin Lispro | Insulin Lispro | 61 | 26 |
| Methimazole | Methimazole | 61 | 11 |
| Metolazone | Metolazone | 60 | 17 |
| Scopolamine | Scopolamine | 59 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 57 | 12 |
| Santyl | Collagenase Clostridium Hist. | 57 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 25 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 56 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 31 |
| Brimonidine Tartrate | Brimonidine Tartrate | 54 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 53 |
| Primidone | Primidone | 54 | suppressed |
| Repaglinide | Repaglinide | 54 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | 14 |
| Heparin Sodium | Heparin Sodium,porcine | 53 | suppressed |
| Irbesartan | Irbesartan | 53 | suppressed |
| Creon | Lipase/Protease/Amylase | 52 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 52 | 19 |
| Ozempic | Semaglutide | 52 | 13 |
| Valacyclovir | Valacyclovir Hcl | 52 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Calcitriol | Calcitriol | 51 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 51 | 13 |
| Nyamyc | Nystatin | 51 | 17 |
| Oxcarbazepine | Oxcarbazepine | 51 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 14 |
| Methotrexate | Methotrexate Sodium | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Budesonide | Budesonide | 49 | 16 |
| Timolol Maleate | Timolol Maleate | 49 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 17 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Colchicine | Colchicine | 47 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | 24 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 46 | 15 |
| Hydrocortisone | Hydrocortisone | 46 | 27 |
| Prednisolone Acetate | Prednisolone Acetate | 46 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 45 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Meloxicam | Meloxicam | 44 | 18 |
| Topiramate | Topiramate | 44 | suppressed |
| Alogliptin | Alogliptin Benzoate | 43 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 26 |
| Ramipril | Ramipril | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 42 | suppressed |
| Acetic Acid | Acetic Acid | 41 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 17 |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Loperamide | Loperamide Hcl | 41 | 31 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 41 | suppressed |
| Tobramycin | Tobramycin | 41 | 36 |
| Lokelma | Sodium Zirconium Cyclosilicate | 39 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 38 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 37 | 11 |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 17 |
| Lacosamide | Lacosamide | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Admelog Solostar | Insulin Lispro | 36 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Humalog | Insulin Lispro | 34 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Lumigan | Bimatoprost | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Letrozole | Letrozole | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 13 |
| Ammonium Lactate | Ammonium Lactate | 32 | 18 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | 15 |
| Anastrozole | Anastrozole | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Clozapine | Clozapine | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 29 | 14 |
| Metronidazole | Metronidazole | 29 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 11 |
| Fiasp | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Daptomycin | Daptomycin | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Febuxostat | Febuxostat | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Felbamate | Felbamate | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Restasis | Cyclosporine | 25 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Acetylcysteine | Acetylcysteine | 20 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Epogen | Epoetin Alfa | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Pentoxifylline | Pentoxifylline | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 12 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 14 |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 15 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Paricalcitol | Paricalcitol | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Carteolol Hcl | Carteolol Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Lotemax | Loteprednol Etabonate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Secuado | Asenapine | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.91 · 27 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, JARDIANCE, Kerendia, LEQVIO, NUPLAZID, OTEZLA, PAXLOVID, REPATHA, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, Zunveyl | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error